Fitzgerald Kevin Joseph 4

What Happened Kevin Joseph Fitzgerald, a member of Ovid Therapeutics' board of directors, was granted 17,578 restricted stock units (RSUs) on 2026-04-07. The grant price/value is reported at $2.56 per share, for an aggregate award value of $45,000. This was an award of equity as compensation (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-04-07; Form 4 filed: 2026-04-09 (filed within the typical 2-business-day reporting window).
• Transaction type/code: Award/Grant (A).
• Award size: 17,578 RSUs at $2.56 per share; total reported value $45,000.
• Vesting: 25% vested upon grant and the remaining 75% vest in three equal installments on 2026-06-30, 2026-09-30 and 2026-12-31, subject to continuous service (footnote F1).
• Purpose: Issued under the issuer’s Non-Employee Director Compensation Policy in lieu of an annual cash retainer.
• Shares owned after transaction: Not disclosed in the filing.
• No tax-withholding or sale details reported in this filing.

Context RSU awards to non-employee directors are typically routine compensation for board service rather than direct signals about insider views. Because 25% of the RSUs vest immediately, a portion may convert to actual shares at grant; remaining portions vest later if the director continues service. This filing reports an award (not a purchase or sale).